三阴乳腺癌治疗瓶颈已属于世界性难题，寻找特异性分子靶点及有效治疗手段具有重要临床意义。在前期实验中发现：三阴乳腺癌细胞中存在着较高比例的CD44+/CD24-乳腺癌干细胞；壳聚糖偶联的纳米脂质体可特异性靶向CD44+乳腺癌干细胞，而不与正常干细胞结合；尾静脉注射的壳聚糖偶联的纳米脂质体可在肿瘤部位选择性分布并长时间停留。以此为基础，本课题以CD44v为靶点，构建壳聚糖修饰的低氧激活型光敏脂质体给药系统，特异性靶向三阴乳腺癌干细胞；在近红外激光照射下，光敏脂质体给药系统中的HPPH被激活而发挥光动力治疗效应；负载的TH302则可在乏氧环境下活化并杀伤乳腺癌干细胞，以弥补光动力学治疗的不足，更高效地清除乳腺癌干细胞，起到协同治疗作用。在体内外实验中，药物的运输、靶向、及治疗效果均可在PET和PAI双模态成像下实现实时观察。

To achieve the efficient therapy of triple negative breast cancer is encouraging but still remains a big challenge worldwide, thus it would be of great clinical significance to discover specific molecular target and effective treatment for TNBC. There were a higher proportion of CD44+/CD24- breast cancer stem cells among TNBC cells as evidenced by numbers of previous trials. Fortunately, chitosan modified nano-liposomes could specifically target CD44+ breast cancer stem cells while circumventing normal stem cells. Besides, chitosan modified nano-liposomes were specifically distribute in tumor sites for a long period via tail vein injection. In this study, chitosan modified hypoxia activated photosensitive liposome drug delivery systems were constructed for specifically targeting TNBC stem cells based on targeting CD44v. HPPH in the drug delivery system were activated to achieve photodynamic therapy upon NIR excitation. TH302 loaded into the system were activated to kill breast cancer stem cells under hypoxia environment. Thus, a synergetic combination of PDT and hypoxia activated chemotherapy could be expected to achieve more effectively eliminate breast cancer cells and unexpected treatment efficiency. Drug delivery, targeting and therapeutic effects could be simultaneously monitored upon PET and PAI bimodal imaging in vitro and vivo.